Fig. 6
From: Antibody targeting of claudin-1 as a potential colorectal cancer therapy
Therapeutic effects of the 6F6 mAb in vivo. a, Effect of the 6F6 mAb on the growth of SW620 cell xenografts in athymic nude mice. Mice were treated or not (black line) with 15 mg/kg twice (light gray line) or three times per week (dark gray line) when tumors reached 100 mm3 (n = 8 animals per group). b, Adapted Kaplan-Meier curves using the time taken to reach a tumor volume of 1500 mm3 in untreated mice (black solid line) and in animals treated with the 6F6 mAb twice (gray solid line) or three times per week (gray dotted line) (log-rank test). c, Effect of the 6F6 mAb on DiFi cell xenografts. Mice received (gray line) or not (dark line) 15 mg/kg of the 6F6 mAb twice per week. d, Effect of the 6F6C mAb on liver metastasis formation. Mice were treated or not with 15 mg/kg of 6F6 three times per week after splenic injection of SW620-LUC cells. Top: number of liver metastases in 6F6-treated and untreated (NT) mice (n = 20/group). C test. Bottom: representative in vivo luminescence images at week 5 after surgery. Five mice are shown for each group